Mecamylamine (Targacept).
Targacept Inc, under license from the University of South Florida, is developing a low-dose, liquid gel capsule formulation of the nicotinic acetylcholine antagonist mecamylamine, as a potential treatment for various neuropsychiatric disorders.
Singh
Abhay
A
Clinical Neuroscience Research Unit, Department of Psychiatry, University of Vermont College of Medicine, 1 South Prospect Street, Burlington, VT 05401, USA. asingh@uvm.edu
Das
Deepak K
DK
Kelley
Michael E
ME
D000293:Adolescent; D000328:Adult; D000818:Animals; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D002648:Child; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008464:Mecamylamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018733:Nicotinic Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016540:Smoking Cessation; D019966:Substance-Related Disorders / Q000188:drug therapy; D005879:Tourette Syndrome / Q000188:drug therapy
D018733:Nicotinic Antagonists; D008464:Mecamylamine